isn't nevaxar further behind though?
Phase 3 trials have not commenced for it yet.
Also considering Bayer could effectively buy into this technology and own the only 2 post risection liver cancer drugs, I would not discount this yet.
Charts are looking bearish bigtime.....
I reckon that extremely price sensitive announcements are coming out this half and it is a good time to capitalise.
Won't be buying yet.....but soon.
TheGimp
